Search Results - "Rubio-Rivas, Manuel"

WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.

Authors: Rubio-Rivas, Manuel Mora-Luján, José María Formiga, Francesc et al.

Source: JGIM: Journal of General Internal Medicine. 2022 Supplement, Vol. 37, p1980-1987. 8p.

The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.

Authors: Rubio-Rivas, Manuel Mora-Luján, José M. Montero, Abelardo et al.

Source: JGIM: Journal of General Internal Medicine. Jan2022, Vol. 37 Issue 1, p168-175. 8p. 1 Diagram, 6 Charts, 2 Graphs.

Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis.

Authors: Rubio‐Rivas, Manuel Forero, Carlos G. Mora‐Luján, José María et al.

Source: Pharmacotherapy. Nov2021, Vol. 41 Issue 11, p884-906. 23p.

The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).

Authors: Pestaña-Fernández, Melani Rubio-Rivas, Manuel Tolosa-Vilella, Carles et al.

Source: Rheumatology. Feb2021, Vol. 60 Issue 2, p872-880. 9p.

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.

Authors: Rubio-Rivas, Manuel Ronda, Mar Padulles, Ariadna et al.

Source: International Journal of Infectious Diseases. Dec2020, Vol. 101, p290-297. 8p.

Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients.

Authors: Rubio-Rivas, Manuel Corbella, Xavier

Source: European Journal of Internal Medicine. Jul2020, Vol. 77, p59-65. 7p.

Sarcoidosis presenting with and without Löfgren's syndrome: Clinical, radiological and behavioral differences observed in a group of 691patients.

Authors: Rubio-Rivas, Manuel Franco, Jonathan Corbella, Xavier

Source: Joint Bone Spine. Mar2020, Vol. 87 Issue 2, p141-147. 7p.

Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry.

Authors: Rubio-Rivas, Manuel Corbella, Xavier Formiga, Francesc et al.

Source: Journal of Clinical Medicine. May2021, Vol. 10 Issue 10, p2214-2214. 1p.

Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.

Authors: Ayala Gutiérrez, María del Mar Rubio-Rivas, Manuel Romero Gómez, Carlos et al.

Source: Journal of Clinical Medicine. May2021, Vol. 10 Issue 9, p1844-1844. 1p.

Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19.

Authors: Rubio-Rivas, Manuel Corbella, Xavier Mora-Luján, José María et al.

Source: Journal of Clinical Medicine. Nov2020, Vol. 9 Issue 11, p3488. 1p.

Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain.

Authors: Rodilla, Enrique Dolores López-Carmona, Maria Cortes, Xavi et al.

Source: Hypertension (0194911X). Mar2021, Vol. 77 Issue 3, p856-867.

First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

Authors: Rubio-Rivas, Manuel Corbella, Xavier Pestaña-Fernández, Melany et al.

Source: Clinical Rheumatology. Apr2018, Vol. 37 Issue 4, p999-1009. 11p. 5 Charts, 2 Graphs.

Occupational and environmental scleroderma. Systematic review and meta-analysis.

Authors: Rubio-Rivas, Manuel Moreno, Rafael Corbella, Xavier

Source: Clinical Rheumatology. Mar2017, Vol. 36 Issue 3, p569-582. 14p.

Tracing In-Hospital COVID-19 Outcomes: A Multistate Model Exploration (TRACE).

Authors: Mohammadi, Hamed Marateb, Hamid Reza Momenzadeh, Mohammadreza et al.

Source: Life (2075-1729). Sep2024, Vol. 14 Issue 9, p1195. 17p.

Correction to: First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.

Authors: Rubio-Rivas, Manuel Corbella, Xavier Pestaña-Fernández, Melany et al.

Source: Clinical Rheumatology. Aug2018, Vol. 37 Issue 8, p2303-2304. 2p.

Corrigendum to 'Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation' [AUTREV 19-5 (2020) 102507].

Authors: Rubio-Rivas, Manuel Corbella, Xavier Guillén-del-Castillo, Alfredo et al.

Source: Autoimmunity Reviews. May2021, Vol. 20 Issue 5, pN.PAG-N.PAG. 1p.

The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis.

Authors: Rubio-Rivas, Manuel Homs, Narcís A. Cuartero, Daniel et al.

Source: Autoimmunity Reviews. Jan2021, Vol. 20 Issue 1, pN.PAG-N.PAG. 1p.

Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma.

Authors: Rubio-Rivas, Manuel Moreira, Catarina Marcoval, J.

Source: Autoimmunity Reviews. Aug2020, Vol. 19 Issue 8, pN.PAG-N.PAG. 1p.

Comment to: Cluster analysis for clinical sarcoidosis' phenotyping.

Authors: Rubio-Rivas, Manuel Corbella, Xavier

Source: European Journal of Internal Medicine. Aug2020, Vol. 78, p142-142. 1p.

Decreasing prevalence and cumulative incidence of scleroderma renal crisis over time: associated factors identified from the RESCLE registry.

Authors: Pla-Salas, Xavier Tolosa-Vilella, Carles Baldà-Masmiquel, Maria et al.

Source: Rheumatology. Dec2025, Vol. 64 Issue 12, p6201-6212. 12p.